Why the study?
High-sensitivity cardiac troponin assays are increasingly used to rapidly rule in or rule out acute coronary syndrome, but there is no consensus on how to compare results across different assays.
Does high-sensitivity cardiac troponin improve the evaluation of acute coronary syndrome in patients with suspected ACS in the emergency setting?
Does high-sensitivity cardiac troponin improve the evaluation of acute coronary syndrome in patients with suspected ACS in the emergency setting?
Answers are grounded in this paper and cite their sources.
This literature review discusses the advantages and limitations of using high-sensitivity cardiac troponin assays for the rapid evaluation of suspected acute coronary syndrome in the emergency department.
Chest pain is one of the most common reasons for an emergency room (ER) visit in the US, with almost 6 million ER visits annually. High-sensitivity cardiac troponin (hscTn) assays have the ability to rapidly rule in or rule out acute coronary syndrome with improved sensitivity, and they are increasingly being used. Though hscTn assays have been approved for use in European, Australian, and Canadian guidelines since 2010, the FDA only approved their use in 2017. There is no consensus on how to compare the results from various hscTn assays. A literature review was performed to analyze the advantages and limitations of using hscTn as a standard biomarker to evaluate patients with suspected ACS in the emergency setting.
No takes yet. Share an insight, caveat, or question.
Narayanan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: